Table 1. In vitro immunoglobulin production and 3H-Thymidin incorporation of PBMCs and lymphoblastoid cells.
immunoglobulin production | |||||||
in vitro (ng/ml) | |||||||
control | patient | ||||||
mean | SD | mean | SD | ||||
unstimulated | IgG | 89 | ± | 37 | n.a. | ||
IgM | 103 | ± | 53 | n.a. | |||
EBV transformed | IgG | 6388 | ± | 4239 | 887 | ± | 76 |
IgM | 24078 | ± | 7946 | 38127 | ± | 1805 | |
3H Thymidin incorporation | |||||||
dpm | |||||||
unstimulated | 1920 | ± | 783 | n.a. | |||
EBV transformed | 75979 | ± | 2795 | 90914 | ± | 305 |
Unstimulated peripheral blood mononuclear cells and EBV-transformed lymphoblastoid cells were incubated for 8 days and the supernatant IgM/G concentration was determined by ELISA. Additionally the 3H-thymidin incorporation was determined. Results are expressed as mean and standard deviation (control unstimulated IgM/G: n = 9; control EBV-transformed IgM/G: n = 3; patient EBV-transformed IgM/G: n = 1 (triplicate); control unstimulated 3H-thymidin incorporation: n = 9; control EBV-transformed 3H-thymidin incorporation: n = 1 (triplicate); patient EBV-transformed 3H-thymidin incorporation: n = 1 (triplicate)).